{
  "created_at": "Wed Dec 15 8:36:32 +0000 2021",
  "id_str": "1470902684047876096",
  "full_text": "Pfizer’s Covid-19 pill, which is up for FDA authorization, worked against Omicron in lab tests, the company said. A final analysis of a key study also confirmed the drug was 89% effective in high-risk adults. https://t.co/2lfPU7arih",
  "display_text_range": [
    0,
    232
  ],
  "entities": {
    "hashtags": [],
    "symbols": [],
    "user_mentions": [],
    "urls": [
      {
        "url": "https://t.co/2lfPU7arih",
        "expanded_url": "https://on.wsj.com/3p3py2d",
        "display_url": "on.wsj.com/3p3py2d",
        "indices": [
          209,
          232
        ]
      }
    ]
  },
  "user": {
    "name": "The Wall Street Journal",
    "screen_name": "WSJ",
    "profile_image_url_https": "https://pbs.twimg.com/profile_images/971415515754266624/zCX0q9d5_normal.jpg"
  },
  "retweet_count": 26,
  "favorite_count": 99,
  "possibly_sensitive": false,
  "original_created_at": "Tue Dec 14 23:45:02 +0000 2021",
  "localize": [
    {
      "locale": "ja",
      "full_text": "FDAの認可申請中のファイザー社のCovid-19錠は、実験室試験でオミクロンに対して効果があったとのことです。また、重要な研究の最終分析では、高リスクの成人において89％の有効性が確認された。https://t.co/2lfPU7arih。"
    },
    {
      "locale": "zh",
      "full_text": "辉瑞公司的Covid-19药片正在等待美国食品和药物管理局的授权，在实验室测试中对Omicron起作用，该公司说。一项关键研究的最终分析也证实，该药物对高风险成人的效果为89%。https://t.co/2lfPU7arih"
    },
    {
      "locale": "zh-Hant",
      "full_text": "輝瑞公司的Covid-19藥片正在等待美國食品和藥物管理局的授權，在實驗室測試中對Omicron起作用，該公司說。一項關鍵研究的最終分析也證實，該藥物對高風險成人的效果爲89%。https://t.co/2lfPU7arih"
    }
  ]
}